This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Inclusion Criteria:

• 1. Patients aged ≥18 years old
• 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
• 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
• 4.Prior or current use of Zanubrutinib for ≥3 months
• 5.At least one follow-up was recorded during Zanubrutinib treatment

Exclusion Criteria:

-

Investigators participating in this observational study should include all patients with CLL who initiated treatment with zanubrutinib over the period from July 1st, 2020 to the present, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.